We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Technique for Correcting Molecular Defects

By Biotechdaily staff writers
Posted on 17 Jan 2003
A study has shown that it is possible to correct defective molecular splicing pathways that would otherwise contribute to cancer and genetic diseases. More...
The study was published in the December 20, 2002, issue of the Journal of Biological Chemistry.

Researchers made these corrections by inserting short strands of genetic material that target portions of RNA into the cell of antisense oligonucleotides. RNA carries the DNA blueprint for cellular protein production in gene expression. The technique was pioneered by Dr. Ryszard Kole, professor of pharmacology at the School of Medicine at the University of North Carolina at Chapel Hill (USA). Dr. Kole and colleagues used the technique to eradicate certain cancer cells to increase their sensitivity to treatment.

Tumors frequently become resistant when cancer cells no long respond to signaling molecules that cause apoptosis. In the study, RNA splicing of the bcl-x gene that controls apoptosis was targeted with antisense oligonucleotides. These antisense molecules were used to shift the alternative splicing of the gene from the anti-apoptotic form to the pro-apoptotic form in cancer cell lines. In so doing, the researchers were able to sensitize these cell lines to various chemotherapeutic agents and radiation.

"This approach could offer a significant advantage over conventional therapies, which are nonspecific and kill both cancerous and noncancerous cells,” said Dr. Danielle Mercatante, first author of the study and a postdoctoral fellow at UNC Comprehensive Cancer Center.




Related Links:
Univ.of North Carolina School of Med

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.